Durable Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated with Fimepinostat (CUDC-907): Combined Results from a Phase 1 and Phase 2 Study
- Resource Type
- Abstract
- Source
- In
Clinical Lymphoma, Myeloma and Leukemia September 2018 18 Supplement 1:S279-S279 - Subject
- Language
- ISSN
- 2152-2650